A Single-centre, One-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Male and Female Subjects
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Dalpiciclib (Primary) ; Omeprazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 11 Jan 2022 Planned End Date changed from 15 Nov 2021 to 15 Mar 2022.
- 11 Jan 2022 Planned primary completion date changed from 15 Oct 2021 to 30 Jan 2022.